Your browser doesn't support javascript.
loading
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Han, Xiaohong; Zhang, Mingzhi; Wang, Huaqing; Zhang, Qingyuan; Li, Wei; Hao, Miaowang; Gao, Yuhuan; Jin, Jie; Ren, Hanyun; Tang, Yun; Hong, Xiaonan; Ke, Xiaoyan; Su, Hang; Gui, Lin; Luo, Jianmin; Xie, Liangzhi; Gai, Wenlin; Shi, Yuankai.
Afiliación
  • Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy
  • Zhang M; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Wang H; Department of Medical Oncology, Tianjin People's Hospital, Tianjin 300121, China.
  • Zhang Q; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • Li W; Oncology Department of Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.
  • Hao M; Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
  • Gao Y; Department of Hematology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Jin J; Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
  • Ren H; Department of Hematology, Peking University First Hospital, Beijing 100034, China.
  • Tang Y; Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Hong X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Ke X; Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
  • Su H; Department of Lymphoma, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
  • Gui L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
  • Luo J; Department of Hematology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
  • Xie L; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.
  • Gai W; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Chin J Cancer Res ; 34(6): 601-611, 2022 Dec 30.
Article en En | MEDLINE | ID: mdl-36714342
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Chin J Cancer Res Año: 2022 Tipo del documento: Article Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Chin J Cancer Res Año: 2022 Tipo del documento: Article Pais de publicación: China